All Access Articles |
- Ionis Pharmaceuticals Stock Drops 3.1% – Key Takeaways | 2025-09-15 | PHARMACEUTICAL
- Ionis Pharmaceuticals Reports Positive Phase 3 Results for Olezarsen in Severe Hypertriglyceridemia | 2025-09-02 | PHARMACEUTICAL
- FDA Approves Ionis Pharmaceuticals' Dawnzera™ for Hereditary Angioedema | 2025-08-22 | PHARMACEUTICAL
- Ionis Pharmaceuticals' Dawnzera™ Approved by FDA for Hereditary Angioedema | 2025-08-21 | PHARMACEUTICAL
- What Every Investor Must Know About IONS Stock | 2025-08-20 | PHARMACEUTICAL
- Investing Insights – Ionis Pharmaceuticals Stock Analysis | 2025-08-14 | PHARMACEUTICAL
- Analysts Assess Ionis Pharmaceuticals (IONS) Amid High Valuation | 2025-08-07 | PHARMACEUTICAL
- Ionis Pharmaceuticals Doubles Revenue in Q2 2025 | 2025-07-30 | PHARMACEUTICAL
- What Ionis Pharmaceuticals Investors Need to Know | 2025-06-18 | PHARMACEUTICAL
- Ionis Pharma's Chief Development Officer to Retire | 2025-06-12 |
- Ionis Pharmaceuticals Reports Positive Results for Olezarsen | 2025-05-19 | PHARMACEUTICAL
- What Are the Tailwinds for IONS? | 2023-04-18 | PHARMACEUTICAL